scholarly journals A Clinical Study of Autologous Bone Marrow Mononuclear Cells for Cerebral Palsy Patients: A New Frontier

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Alok Sharma ◽  
Hemangi Sane ◽  
Nandini Gokulchandran ◽  
Pooja Kulkarni ◽  
Sushant Gandhi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cerebral Palsy ◽  
Mononuclear Cells ◽  
Cellular Therapy ◽  
Autologous Bone Marrow ◽  
Bone Marrow Mononuclear Cells ◽  
Open Label ◽  
Pet Ct ◽  
Study Population ◽  
Autologous Bone

Cerebral palsy is a nonprogressive heterogeneous group of neurological disorders with a growing rate of prevalence. Recently, cellular therapy is emerging as a potential novel treatment strategy for cerebral palsy. The various mechanisms by which cellular therapy works include neuroprotection, immunomodulation, neurorestoration, and neurogenesis. We conducted an open label, nonrandomized study on 40 cases of cerebral palsy with an aim of evaluating the benefit of cellular therapy in combination with rehabilitation. These cases were administered autologous bone marrow mononuclear cells intrathecally. The follow-up was carried out at 1 week, 3 months, and 6 months after the intervention. Adverse events of the treatment were also monitored in this duration. Overall, at six months, 95% of patients showed improvements. The study population was further divided into diplegic, quadriplegic, and miscellaneous group of cerebral palsy. On statistical analysis, a significant association was established between the symptomatic improvements and cell therapy in diplegic and quadriplegic cerebral palsy. PET-CT scan done in 6 patients showed metabolic improvements in areas of the brain correlating to clinical improvements. The results of this study demonstrate that cellular therapy may accelerate the development, reduce disability, and improve the quality of life of patients with cerebral palsy.

scholarly journals Autologous Bone Marrow Mononuclear Cells in Ischemic Cerebrovascular Accident Paves Way for Neurorestoration: A Case Report

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Alok Sharma ◽  
Hemangi Sane ◽  
Anjana Nagrajan ◽  
Nandini Gokulchandran ◽  
Prerna Badhe ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Ischemic Stroke ◽  
Mononuclear Cells ◽  
Cellular Therapy ◽  
Functional Independence Measure ◽  
Autologous Bone Marrow ◽  
Functional Independence ◽  
Bone Marrow Mononuclear Cells ◽  
Autologous Bone

In response to acute ischemic stroke, large numbers of bone marrow stem cells mobilize spontaneously in peripheral blood that home onto the site of ischemia activating the penumbra. But with chronicity, the numbers of mobilized cells decrease, reducing the degree and rate of recovery. Cellular therapy has been explored as a new avenue to restore the repair process in the chronic stage. A 67-year-old Indian male with a chronic right middle cerebral artery ischemic stroke had residual left hemiparesis despite standard management. Recovery was slow and partial resulting in dependence to carry out activities of daily living. Our aim was to enhance the speed of recovery process by providing an increased number of stem cells to the site of injury. We administered autologous bone marrow mononuclear cells intrathecally alongwith rehabilitation and regular follow up. The striking fact was that the hand functions, which are the most challenging deficits, showed significant recovery. Functional Independence Measure scores and quality of life improved. This could be attributed to the neural tissue restoration. We hypothesize that cell therapy may be safe, novel and appealing treatment for chronic ischemic stroke. Further controlled trials are indicated to advance the concept of Neurorestoration.

scholarly journals IMPROVEMENTS IN A CASE OF SENSORY ATAXIA THROUGH CELL TRANSPLANTATION

2019 ◽  
Vol 3 (2) ◽  
Author(s):  
Alitta Jose
Keyword(s):  
Mononuclear Cells ◽  
Rating Scale ◽  
Cellular Therapy ◽  
Autologous Bone Marrow ◽  
Emission Tomography ◽  
Bone Marrow Mononuclear Cells ◽  
Sensory Ataxia ◽  
Positron Emission ◽  
Pet Ct ◽  
Autologous Bone

Sensory ataxia is a type of ataxia that is caused by the loss of sensory input to control the movement of the body.  It is both a sign and a symptom. There have been no curative modalities for treating sensory ataxia. Cellular therapy has gained significant attention as a therapeutic option for various neurological disorders. We present a case of an 18-year-old female diagnosed with sensory ataxia who was intrathecally administered with autologous bone marrow mononuclear cells (BMMNCs) along with neurorehabilitation. Twelve months after cellular therapy, signs such as ataxia, postural tremors, intention tremors and dysmetria improved. Functional Independence Measure score improved from 106 to 107. Berg Balance Scale improved from 18 to 34. Brief Ataxia Rating Scale improved from 7 to 5. Modified International Cooperative Ataxia Rating Scale improved 26 to 24. Comparison of the Positron Emission Tomography Computed-Tomography (PET CT) image before and 12 months after cellular therapy showed improved metabolism in bilateral sensory motor cortex, thalamus and cerebellum. These PET findings correlated with symptomatic improvements. The clinical improvements along with PET CT findings suggest that cellular therapy is a beneficial therapeutic modality for sensory ataxia. No major adverse effects were seen. Further clinical studies should be conducted to understand the efficacy of cellular therapy in sensory ataxia.  Keywords: Sensory ataxia; Cellular therapy; Autologous Bone Marrow Mononuclear Cells; Positron Emission Tomography Computed Tomography.

Sign in / Sign up

Export Citation Format

Share Document